Percutaneous mitral-valve intervention for secondary mitral regurgitation: data from real-life
<p dir="ltr">Many questions were raised due to the divergent results between COAPT and MITRA-FR trials on the use of percutaneous mitral valve repair (PMVr) for secondary mitral regurgitation (SMR). This paper examined pooled patients’ characteristics and outcomes from real-life expe...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , |
| منشور في: |
2023
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513550839447552 |
|---|---|
| author | Rasha Kaddoura (12506936) |
| author2 | Daoud Al-Badriyeh (832403) Dina Abushanab (10696501) Mohammed Al-Hijji (4050934) |
| author2_role | author author author |
| author_facet | Rasha Kaddoura (12506936) Daoud Al-Badriyeh (832403) Dina Abushanab (10696501) Mohammed Al-Hijji (4050934) |
| author_role | author |
| dc.creator.none.fl_str_mv | Rasha Kaddoura (12506936) Daoud Al-Badriyeh (832403) Dina Abushanab (10696501) Mohammed Al-Hijji (4050934) |
| dc.date.none.fl_str_mv | 2023-10-01T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.cpcardiol.2023.101889 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Percutaneous_mitral-valve_intervention_for_secondary_mitral_regurgitation_data_from_real-life/23540784 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences edge-to-edge MitraClip mitral regurgitation transcatheter repair Drug Information Center (HMC) |
| dc.title.none.fl_str_mv | Percutaneous mitral-valve intervention for secondary mitral regurgitation: data from real-life |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Many questions were raised due to the divergent results between COAPT and MITRA-FR trials on the use of percutaneous mitral valve repair (PMVr) for secondary mitral regurgitation (SMR). This paper examined pooled patients’ characteristics and outcomes from real-life experience compared with those in the two landmark trials. A comprehensive search identified eligible studies published in 2020 and 2021. Mean difference and odds ratio (OR) were used to compare continuous and categorical data. Thirty-three studies included more than 9200 patients. Patients in landmark trials were younger than in real-life, less likely to present with severe heart failure symptoms [(COAPT: OR 0.25; 95% CI: 0.21, 0.31); (MITRA-FR: OR 0.32; 95% CI: 0.23, 0.45)] or severe MR grade (COAPT only: OR 0.57; 95% CI: 0.45, 0.71) with larger left ventricular end diastolic volume. Procedure success (OR 1.94; 95% CI: 1.10, 3.40) was more frequent with lower all-cause mortality (OR 0.73; 95% CI: 0.54, 0.99) in COAPT. Real-life patients experienced more favorable procedural and clinical outcomes compared with MITRA-FR patients. Real-life data on PMVr in SMR showed important variations in patient selection and procedural outcomes. Rates of death and heart failure hospitalization in observational studies were lower than MITRA-FR but higher than COAPT trial.</p><h2>Other Information</h2><p dir="ltr">Published in: Current Problems in Cardiology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1016/j.cpcardiol.2023.101889" target="_blank">http://dx.doi.org/10.1016/j.cpcardiol.2023.101889</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_8da3c85766525fadeda666d196b09c21 |
| identifier_str_mv | 10.1016/j.cpcardiol.2023.101889 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/23540784 |
| publishDate | 2023 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Percutaneous mitral-valve intervention for secondary mitral regurgitation: data from real-lifeRasha Kaddoura (12506936)Daoud Al-Badriyeh (832403)Dina Abushanab (10696501)Mohammed Al-Hijji (4050934)Biomedical and clinical sciencesCardiovascular medicine and haematologyPharmacology and pharmaceutical sciencesedge-to-edgeMitraClipmitral regurgitationtranscatheter repairDrug Information Center (HMC)<p dir="ltr">Many questions were raised due to the divergent results between COAPT and MITRA-FR trials on the use of percutaneous mitral valve repair (PMVr) for secondary mitral regurgitation (SMR). This paper examined pooled patients’ characteristics and outcomes from real-life experience compared with those in the two landmark trials. A comprehensive search identified eligible studies published in 2020 and 2021. Mean difference and odds ratio (OR) were used to compare continuous and categorical data. Thirty-three studies included more than 9200 patients. Patients in landmark trials were younger than in real-life, less likely to present with severe heart failure symptoms [(COAPT: OR 0.25; 95% CI: 0.21, 0.31); (MITRA-FR: OR 0.32; 95% CI: 0.23, 0.45)] or severe MR grade (COAPT only: OR 0.57; 95% CI: 0.45, 0.71) with larger left ventricular end diastolic volume. Procedure success (OR 1.94; 95% CI: 1.10, 3.40) was more frequent with lower all-cause mortality (OR 0.73; 95% CI: 0.54, 0.99) in COAPT. Real-life patients experienced more favorable procedural and clinical outcomes compared with MITRA-FR patients. Real-life data on PMVr in SMR showed important variations in patient selection and procedural outcomes. Rates of death and heart failure hospitalization in observational studies were lower than MITRA-FR but higher than COAPT trial.</p><h2>Other Information</h2><p dir="ltr">Published in: Current Problems in Cardiology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1016/j.cpcardiol.2023.101889" target="_blank">http://dx.doi.org/10.1016/j.cpcardiol.2023.101889</a></p>2023-10-01T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.cpcardiol.2023.101889https://figshare.com/articles/journal_contribution/Percutaneous_mitral-valve_intervention_for_secondary_mitral_regurgitation_data_from_real-life/23540784CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/235407842023-10-01T00:00:00Z |
| spellingShingle | Percutaneous mitral-valve intervention for secondary mitral regurgitation: data from real-life Rasha Kaddoura (12506936) Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences edge-to-edge MitraClip mitral regurgitation transcatheter repair Drug Information Center (HMC) |
| status_str | publishedVersion |
| title | Percutaneous mitral-valve intervention for secondary mitral regurgitation: data from real-life |
| title_full | Percutaneous mitral-valve intervention for secondary mitral regurgitation: data from real-life |
| title_fullStr | Percutaneous mitral-valve intervention for secondary mitral regurgitation: data from real-life |
| title_full_unstemmed | Percutaneous mitral-valve intervention for secondary mitral regurgitation: data from real-life |
| title_short | Percutaneous mitral-valve intervention for secondary mitral regurgitation: data from real-life |
| title_sort | Percutaneous mitral-valve intervention for secondary mitral regurgitation: data from real-life |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences edge-to-edge MitraClip mitral regurgitation transcatheter repair Drug Information Center (HMC) |